
The collaborative agreement between Novo Nordisk and the global company SomaLogic means that the Danish pharmaceutical company can use the technology platform SomaScan for the development of treatments, for example (NASH), cardiovascular diseases and diabetes, according to a SomaLogic press release.
According to SomaLogic, the technology platform could potentially identify new biomarkers, novel drug targets and improve the assessment and management of therapeutic responses.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app